Home > Akt & Akt & > Perifosine

Perifosine

哌立福辛,NSC-639966,KRX-0401

Perifosine (KRX-0401)是一种新型的Akt抑制剂,IC50为4.7 μM,靶向作用于Akt的pleckstrin homology (PH)区。

目录号
EY1645
EY1645
EY1645
EY1645
EY1645
纯度
99.37%
99.37%
99.37%
99.37%
99.37%
规格
1 mg
5 mg
10 mg
50 mg
100 mg
原价
400
1000
1890
6302
8600
售价
400
1000
1890
6302
8600
库存
现货
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    Perifosine is a synthetic antitumor alkylphospholipid. It induces cell apoptosis through inhibiting the activity of Akt. Perifosine shows antitumor activity in various cell lines including NSCLC, MM, epithelial carcinoma, prostate carcinoma and leukemia cells. In H460 cells, perifosine decreased cell survival and induced apoptosis with IC50 values of 1μM and 10 μM, respectively. The treatment of perifosine was also found to induce cleavage of caspase-8, caspase-9, caspase-3 and PARP in this cell line. In MM.1S cells, perifosine induced sub-G1 phase population increase from 15% to 57% at 10 μM and induced cleavage of caspase-8, caspase-9 and PARP in a dose-dependent manner. In mice inoculated with MM.1S cells, oral administration of perifosine significantly reduced MM tumor growth and increased survival.

  • 体外研究

  • 体内研究

    30% Propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)

  • 激酶实验

  • 细胞实验

    0, 15, 30,45 μM

  • 动物实验

    250 mg/kg/wk或者36 mg/kg/d 口服

  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Vyomesh Patel, et al. Cancer Res, 2002, 62(5), 1401-1409.
    [2] Fu et al (2009) Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 69 8967.
    [3] Tazzari et al (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 68 9394.
    [4] Delgado-Ramírez et al (2016) Modulation of the voltage-gated potassium channel Kv2.1 by the anti-tumor alkylphospholipid perifosine. Pharmacol Rep. 68 457.

    分子式
    C25H52NO4P
    分子量
    461.66
    CAS号
    157716-52-4
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    <1 mg/mL
    Water
    8 mg/mL
    Ethanol
    15 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00590954 Malignant Gliomas|CNS|Brain Cancer|Cancer Drug: Perifosine Memorial Sloan Kettering Cancer Center|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Online Collaborative Oncology Group|University of Wisconsin, Madison|Columbia University Phase 2 2006-05-01 2016-06-01
    NCT01049841 Pediatric Solid Tumors Drug: perifosine + temsirolimus Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris Phase 1 2010-01-01 2017-03-09
    NCT00873457 Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma Drug: perifosine Daphne Friedman|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Duke University Phase 2 2009-08-01 2013-05-19
    NCT00422656 Waldenstrom's Macroglobulinemia Drug: Perifosine Dana-Farber Cancer Institute Phase 2 2006-09-01 2013-10-16
    NCT00398879 Colon Cancer Drug: Perifosine in combination with capecitabine AEterna Zentaris Phase 2 2005-08-01 2013-03-04
    NCT00498966 Kidney Cancer Drug: Perifosine AEterna Zentaris Phase 2 2007-07-01 2014-02-14
    NCT01224730 Cancer Drug: perifosine AEterna Zentaris Phase 1 2012-01-01 2012-05-30
    NCT00776867 Solid Tumors Drug: perifosine Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|AEterna Zentaris Phase 1 2008-10-01 2016-09-19
    NCT00391560 Leukemia Drug: perifosine AEterna Zentaris Phase 2 2006-10-01 2013-03-04
    NCT00399789 Non Small Cell Lung Cancer Drug: Perifosine AEterna Zentaris Phase 1|Phase 2 2004-09-01 2014-02-11
    NCT00455559 Gastrointestinal Stromal Tumors Drug: Perifosine|Drug: Imatinib Mesylate AEterna Zentaris|M.D. Anderson Cancer Center Phase 2 2006-08-01 2014-02-14
    NCT00448721 Renal Cell Carcinoma Drug: Perifosine AEterna Zentaris|Dana-Farber Cancer Institute Phase 2 2007-03-01 2014-02-11
    NCT01048580 Colon Cancer Drug: Perifosine + Capecitabine AEterna Zentaris|SCRI Development Innovations, LLC Phase 1 2009-10-01 2014-02-14
    NCT00375791 Multiple Myeloma Drug: perifosine|Drug: dexamethasone AEterna Zentaris Phase 2 2005-12-01 2014-02-11
    NCT00389077 Tumors|Lymphomas Drug: Perifosine Daily Dose|Drug: Perifosine AEterna Zentaris Phase 2 2005-01-01 2014-02-12
    NCT00058214 Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer Drug: perifosine|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 2 2003-03-01 2015-02-09
    NCT00847366 Non Small Cell Lung Cancer|Solid Tumors|Metastatic Breast Cancer|Sarcomas Drug: Perifosine|Drug: Perifosine|Drug: Perifosine|Drug: Perifosine|Drug: Perifosine AEterna Zentaris 2008-05-01 2012-05-28
    NCT00399152 Renal Cancer|GIST Drug: Perifosine|Drug: Sunitinib Malate AEterna Zentaris Phase 1 2006-10-01 2014-02-14
    NCT00398814 Renal Cancer|Tumors Drug: Perifosine|Drug: Sorafenib AEterna Zentaris Phase 1 2006-10-01 2014-02-14
    NCT01051557 Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm Other: Laboratory Biomarker Analysis|Drug: Perifosine|Drug: Temsirolimus|Procedure: Therapeutic Conventional Surgery National Cancer Institute (NCI) Phase 1|Phase 2 2010-01-01 2017-03-03

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :